On Dec. 22, 2023, the U.S. Centers for Disease Control and Prevention (CDC) announced study results that showed SARS-CoV-2 rebounded with and without the use of antiviral treatment that were described in previous studies. The definition of and methods assessing SARS-CoV-2 rebound, including frequency and duration of specimen collection, varied among studies (Table 2). No hospitalizations or deaths were reported among outpatients who experienced rebound, because symptoms were mild.